Long-term real-world study of Dupilumab for eosinophilic esophagitis
Treatments studied
Part of Blood & lymphatic, Digestive system, Immune system & allergy clinical trials.
This study looks at how well Dupilumab works over time in people aged 12 and older with eosinophilic esophagitis (EoE) whose symptoms are not well controlled by standard treatments. It aims to understand the medicine's effects in everyday medical practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years or older and weigh at least 40 kg (about 88 pounds).
- You have been diagnosed with eosinophilic esophagitis (EoE).
- Your EoE is not well controlled with standard treatments, or you cannot take them.
- You have started Dupilumab within the last 7 days or your doctor plans to start it now.
- You are willing to participate and sign a consent form (a parent or guardian may need to sign too).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two treatments for EoE that has caused narrowing in the esophagus: dupilumab (a biologic injection) versus a topical corticosteroid (a swallowed steroid). It aims to see which works better for teens and young adults to improve swallowing and reduce inflammation.
This study looks at how well dupilumab works over time for people with COPD who still have symptoms despite standard treatments and who have a certain type of inflammation (elevated eosinophils). It uses data from regular doctor visits and patient questionnaires to understand real-world benefits and safety.
This trial tests if dupilumab can help young children with eosinophilic esophagitis (EoE), a condition that causes swelling in the esophagus. It may reduce symptoms and improve how the esophagus heals.
This trial tests if dupilumab, a weekly injection, can improve the muscle function of the esophagus in people with eosinophilic esophagitis (EoE) who haven't gotten better with acid-reducing medications. Researchers want to see if it helps with swallowing and reduces inflammation.
This study compares two medicines—Eohilia (an oral steroid) and Dupixent (an injectable biologic)—to see which one better helps widen the esophagus in people with eosinophilic esophagitis (EoE). It may help you if you have active EoE and are looking for a new treatment option.
This study looks at how well dupilumab works for people with uncontrolled COPD who have high levels of a certain white blood cell (eosinophils). It collects information from routine doctor visits to see how patients feel and if the treatment is safe.
Hear when a new Eosinophilic Esophagitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.